Northeast Indiana Bancorp, Inc. posted a net income of $1.99 million for Q3 2026, up from $1.79 million in the same quarter last year. The bank saw an increase in net interest income and non-interest income, while maintaining stable expenses. Its annualized return on average assets (ROA) rose to 1.45% and return on average equity (ROE) to 14.11%, indicating improved profitability. Total assets slightly decreased, but deposits increased, showing steady customer confidence. The company continues to manage credit losses prudently amid economic uncertainties.
Northeast Indiana Bancorp, Inc. reported a net income of $1.99 million for Q3 2026. For readers following Financials-sector US stocks, here is Pluang's market snapshot as of Oct 28, 2026 21:21 WIB: out of 142 priced stocks, 66 rose and 73 fell. Notable movers include Nu Holdings Ltd at USD 12.02 with a 1-day change of -3.06% and Pluang order activity showing 86% Buy, and Itau Unibanco Banco Holding SA at USD 7.45 with a 1-day change of -2.87% and 95% Buy order activity.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
